News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Sales reflect continued strong growth in oncology and vaccines
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
